Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 444 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: unfractionated heparin Clear all
Not listed Phase 4 Interventional

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

NCT03965208
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Anticoagulants
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.

NCT00878826
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 4, 2026, 1:11 AM EDT
Terminated Phase 3 Interventional Results available

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

NCT05658874
View directory record Official record
Conditions
Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions
Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin
Drug · Procedure · Behavioral + 1 more
Lead sponsor
Jocelyn Fitzgerald
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing Two Bladder Instillations for IC/BPS

NCT03463915
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Bladder instillation WITH triamcinolone acetonide, Bladder instillation WITHOUT triamcinolone acetonide
Drug
Lead sponsor
Olivia Cardenas-Trowers, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 4, 2026, 1:11 AM EDT
Terminated Not applicable Interventional Results available

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

NCT04764396
View directory record Official record
Conditions
Pancreas, Mass Lesion
Interventions
Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe), Saline
Combination Product · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 2 Interventional

The Female Microbiome in Patients Undergoing Bladder Instillation Therapy

NCT05414305
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome, Microbial Colonization
Interventions
Heparin & Alkalinized Lidocaine Bladder Instillation
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 1 Interventional Results available

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

NCT01241903
View directory record Official record
Conditions
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions
rosuvastatin, placebo
Drug
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antimicrobial Catheter Lock

NCT00571259
View directory record Official record
Conditions
Bacteremia
Interventions
Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL
Drug
Lead sponsor
Satellite Healthcare
Other
Eligibility
Not listed
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 4, 2026, 1:11 AM EDT
Not listed Phase 3 Interventional

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

NCT00628680
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
AAT-023 solution (Zuragen), Heparin
Device · Drug
Lead sponsor
Ash Access Technology
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
22
States / cities
Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 4, 2026, 1:11 AM EDT
Terminated Phase 1 Interventional Results available

Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

NCT04994977
View directory record Official record
Conditions
Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma
Interventions
Melphalan, Carboplatin, Topotecan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
0 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 4, 2026, 1:11 AM EDT
Suspended Phase 2 Interventional

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

NCT02501434
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
Interventions
Continuous Low-Dose IV Unfractionated Heparin Infusion
Drug
Lead sponsor
Robert F. James
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 4, 2026, 1:11 AM EDT
Withdrawn Phase 1 Interventional

Bivalirudin vs Heparin in ECMO Patients

NCT03707418
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication
Interventions
Heparin Sodium, Bivalirudin Injection [Angiomax]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 1 Interventional

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

NCT02995655
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
Interventions
CX-01, Azacitidine, Bone marrow biopsy, Peripheral blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 4, 2026, 1:11 AM EDT
Not listed No phase listed Observational

Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)

NCT00946400
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
Scoring 4Ts and Chong scale, Blood draw
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2009 · Synced Sep 4, 2026, 1:11 AM EDT
Active, not recruiting Not applicable Interventional

The PEERLESS II Study

NCT06055920
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 1:11 AM EDT
Not listed No phase listed Observational

Pharmacogenomics of Heparin-Induced Thrombocytopenia

NCT02717039
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Blood Draw
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 4, 2026, 1:11 AM EDT
Terminated Phase 4 Interventional Results available

Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes

NCT02923830
View directory record Official record
Conditions
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Interventions
Heparinized saline catheter flush, Saline-only catheter flush
Other · Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Cincinnati, Ohio • Hamilton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Upper Extremity Deep-Vein Thrombosis

NCT00245856
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Dalteparin sodium injection, Warfarin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 1 Interventional

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

NCT02687256
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Extended Wear infusion set, Standard Infusion set, Heparin
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 2 Interventional

Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI

NCT00715455
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
REG1, Unfractionated Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Indianapolis, Indiana • Detroit, Michigan • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 4, 2026, 1:11 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

NCT00721760
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin sodium, Semuloparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 4, 2026, 1:11 AM EDT